Zonulin IgG/IgA/IgM

If you have been told your gut might be "leaky," or you carry an autoimmune condition, persistent fatigue, or stubborn metabolic problems that standard labs can't explain, this is the test that tries to put a number on what's happening at the lining of your intestine. It measures antibodies your immune system has built against zonulin, a protein that loosens the seals between gut cells.

A single blood draw for zonulin protein itself can swing widely from hour to hour. The antibodies against zonulin (best characterized for IgG and IgA) are more stable, which is why researchers turned to them when the protein measurement kept giving inconsistent answers in the same person on the same day.

What This Test Actually Measures

This test looks for three classes of immune proteins (IgG, IgA, and IgM, all known as immunoglobulins) that your body has produced against zonulin. The best stability and clinical data exist for IgG and IgA; IgM is less well-characterized and is included for completeness. Zonulin is a protein that signals the tight junctions, the seal-like connections between the cells lining your intestine, to loosen. When those junctions open too easily or too often, large food particles, microbes, and bacterial fragments can slip from the gut into the bloodstream.

Antibodies against zonulin are thought to reflect that this loosening has been happening repeatedly. In a study of 18 controls, the zonulin protein itself fluctuated significantly across a 30 hour window in most people (12 of 18), while IgG and IgA antibodies to zonulin were described as highly stable and reproducible from sample to sample across 0, 6, 24, and 30 hours. That stability is the main reason the antibody version exists.

Why This Is an Exploratory Test, Not a Verdict

Be honest with yourself about where this marker sits in clinical medicine. There are no standardized cutpoints for zonulin IgG/IgA/IgM in plasma. The field has not agreed on what counts as "normal," and even the underlying zonulin assays have come under scrutiny. Independent investigations found that widely used commercial zonulin ELISAs do not actually bind to pre-haptoglobin-2 (the true zonulin protein); instead, they appear to detect properdin, complement C3, and haptoglobin.

There is also a biological limitation worth knowing. Zonulin (pre-haptoglobin-2) is only produced by people who carry the HP2 version of the haptoglobin gene (HP1-2 or HP2-2 genotype). Individuals who carry two copies of HP1 (HP1-1) do not produce detectable zonulin, which means a subset of the population may show low or absent zonulin antibody signals for genetic rather than clinical reasons.

This is a research-stage marker. It can give you a directional read on gut barrier biology and complement other markers, but you should not treat a single result as a diagnosis. The right way to use it is as one input among several, tracked over time, in a person who has a concrete reason to think the gut barrier is part of their problem.

Celiac Disease and Gut-Driven Autoimmunity

The strongest signal for zonulin antibodies is in celiac disease, a condition where the immune system attacks the gut lining in response to gluten. In a celiac cohort, mean serum zonulin protein was higher in patients than controls, but only about 37% of celiac patients had zonulin protein levels elevated more than two standard deviations above the control mean.

The antibody picture was sharper. IgG and IgA antibodies against zonulin, occludin (another tight junction protein), and other tight junction proteins were detected in up to about 86% of celiac patients. In plain terms, the antibody version flagged the gut barrier problem in a larger proportion of celiac patients than the protein version.

What this means for you: if you have celiac disease, suspected non-celiac gluten sensitivity, or a first-degree relative with celiac, this marker can give you a more sensitive read on whether your gut barrier is still being breached than a one-time zonulin protein draw.

Long COVID and Post-Viral Syndromes

In a study comparing people with Long COVID to healthy controls, researchers measured IgA and IgG antibodies against a combined zonulin and occludin target (called ZOOC) alongside antibodies to bacterial fragments and viruses. A statistical model combining IgG-ZOOC, IgA-ZOOC, and antibodies to bacterial cell-wall fragments distinguished Long COVID from controls with an area under the curve of 0.755, where a perfect test scores 1.0 and a coin flip scores 0.5. That represents moderate, not high, discriminatory accuracy.

A subsequent systematic review reported that Long COVID patients were significantly more likely than controls to carry autoantibodies against zonulin and occludin across all three isotypes, with the strongest signal for IgG. The same primary study found that the variation in immune responses against myelin (the protective coating around nerves) was largely explained by autoimmunity to ZOOC, and this was linked to reactivation of human herpesvirus 6. The clinical takeaway is narrower than the science: people with persistent fatigue, brain fog, or autoimmune-flavored symptoms after viral illness are a group where these antibodies seem to track something real, but the test is still being studied as a research marker, not a diagnostic for Long COVID.

How This Compares to Standard Zonulin Protein

If you have ever ordered a serum zonulin test and gotten a result that didn't seem to match how you felt, you are not alone. The protein version has two problems the antibody version partially solves.

• Hour-to-hour fluctuation: in most healthy volunteers tested, zonulin protein levels varied significantly across a 30 hour window. IgG and IgA antibodies in the same volunteers were highly stable across the same window.
• Detection limit issues: a portion of those volunteers (6 of 18) had zonulin levels so low they were near the assay's floor, making the readings unreliable in either direction.
• Assay specificity questions: commercial zonulin ELISAs may bind to proteins other than zonulin itself, including properdin, complement C3, and haptoglobin, so the absolute number you see may not represent what the label claims.

None of this means the antibody version is perfect. It is just more stable and, in the conditions where it has been studied, more often abnormal in people who actually have gut barrier problems.

Reconciling the Mixed Signals in This Field

You may notice that the surrounding research on zonulin protein keeps coming up across very different diseases: kidney disease, obesity, metabolic syndrome, multiple sclerosis, and more. That doesn't mean zonulin is a universal marker. It more likely reflects that the gut barrier is touched by a wide range of conditions, and that the assays measuring it are not specific enough to point at one diagnosis. Treat this test as a barrier-integrity signal that becomes useful when paired with the right clinical context, not as a stand-alone diagnostic for any one disease.

Why One Reading Is Not Enough

Because there are no standardized clinical cutpoints, the most useful thing you can do is establish your own baseline and watch the trend. A single isolated number gives you almost nothing to act on. A baseline followed by repeat testing 3 to 6 months later, especially around a deliberate change such as eliminating gluten, treating a known infection, or starting a gut-focused protocol, gives you a trajectory.

The antibody version is well-suited to this kind of trending because, unlike the protein, it does not bounce around within a single day. Practical cadence: baseline now, repeat in 3 to 6 months if you are making changes, then at least annually if you have a chronic condition where gut barrier dysfunction is plausible.

When Results Can Be Misleading

• Assay variability: zonulin and zonulin-antibody assays are not standardized across labs. A result from one lab is not directly comparable to a result from another. Stick with the same lab when trending.
• Haptoglobin genotype: people who are homozygous for HP1 do not produce zonulin (pre-haptoglobin-2), which can lead to low or absent antibody signals for genetic rather than clinical reasons.
• Acute infections and recent illness: the immune system mounts antibody responses to many triggers, and a recent gut infection, food poisoning, or systemic illness can transiently shift antibody profiles. Avoid drawing this test in the weeks immediately after an acute illness.
• Unclear target specificity: because some zonulin assays detect related proteins rather than zonulin alone, your antibody result may reflect immune responses to a family of related molecules, not zonulin specifically. This does not invalidate the result, but it does mean you should interpret the absolute number with caution.
• Population differences: most published data come from people with specific diagnoses (celiac disease, Long COVID, autoimmune conditions). Healthy reference ranges are still being established.

What an Out-of-Pattern Result Should Prompt

If your antibodies come back elevated and you have not been worked up for celiac disease, that is the first conversation to have. Tissue transglutaminase IgA and total IgA are the standard initial labs, and a gastroenterology referral for endoscopy is appropriate if those are positive. If celiac is excluded but you have gut symptoms, fatigue, or autoimmune features, the elevated antibodies become one data point in a broader workup.

Pair this result with other intestinal barrier and inflammation markers: hs-CRP for systemic inflammation, ferritin for iron status (often low when the gut isn't absorbing well), and B12 and folate for absorption integrity. A stool calprotectin can clarify whether there is active gut inflammation alongside the barrier signal. If your pattern suggests post-viral or post-infectious gut involvement, an Epstein-Barr virus panel or human herpesvirus 6 testing may be relevant.

Specialists to consider: a gastroenterologist if celiac or inflammatory bowel disease is on the table, a rheumatologist if autoimmune symptoms dominate, and a functional or integrative medicine clinician if you want a broader gut-focused workup. The result alone is rarely a reason to act; the combination of result, symptoms, and companion labs is.